J E Chaft
Overview
Explore the profile of J E Chaft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
1160
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shaverdian N, Beattie J, Thor M, Offin M, Shepherd A, Gelblum D, et al.
Ann Oncol
. 2020 Oct;
31(12):1719-1724.
PMID: 33010460
Background: Immune checkpoint inhibitors (ICIs) and thoracic radiotherapy are increasingly used to treat advanced cancers. Despite data indicating exaggerated radiation toxicities in patients with autoimmune disease, the safety of thoracic...
2.
Luo J, Rizvi H, Preeshagul I, Egger J, Hoyos D, Bandlamudi C, et al.
Ann Oncol
. 2020 Jun;
31(10):1386-1396.
PMID: 32561401
Background: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer...
3.
Cottrell T, Thompson E, Forde P, Stein J, Duffield A, Anagnostou V, et al.
Ann Oncol
. 2018 Jul;
29(8):1853-1860.
PMID: 29982279
Background: Neoadjuvant anti-PD-1 may improve outcomes for patients with resectable NSCLC and provides a critical window for examining pathologic features associated with response. Resections showing major pathologic response to neoadjuvant...
4.
Derosa L, Hellmann M, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al.
Ann Oncol
. 2018 Apr;
29(6):1437-1444.
PMID: 29617710
Background: The composition of gut microbiota affects antitumor immune responses, preclinical and clinical outcome following immune checkpoint inhibitors (ICI) in cancer. Antibiotics (ATB) alter gut microbiota diversity and composition leading...
5.
Osorio J, Ni A, Chaft J, Pollina R, Kasler M, Stephens D, et al.
Ann Oncol
. 2016 Dec;
28(3):583-589.
PMID: 27998967
Background: Programmed cell death protein-1 (PD-1) blockade therapies have demonstrated durable responses and prolonged survival in a variety of malignancies. Treatment is generally well tolerated although immune-related adverse events (irAEs)...
6.
Hellmann M, Li B, Chaft J, Kris M
Ann Oncol
. 2016 Jul;
27(10):1829-35.
PMID: 27456296
Molecularly targeted and immunotherapies have improved the care of patients with lung cancers. These successes have rallied calls to replace or avoid chemotherapy. Yet, even in this era of precision...